BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 330 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2022. The put-call ratio across all filers is 0.46 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $4,400,000 | -17.2% | 37,111 | -3.8% | 0.01% | -8.3% |
| Q4 2021 | $5,316,000 | -8.1% | 38,577 | -7.4% | 0.01% | -20.0% |
| Q3 2021 | $5,786,000 | +41.4% | 41,654 | -1.2% | 0.02% | +50.0% |
| Q2 2021 | $4,093,000 | +32.6% | 42,154 | -6.6% | 0.01% | +11.1% |
| Q1 2021 | $3,086,000 | -17.4% | 45,153 | +3.6% | 0.01% | -10.0% |
| Q4 2020 | $3,737,000 | +29.8% | 43,603 | -1.5% | 0.01% | +11.1% |
| Q3 2020 | $2,879,000 | -13.5% | 44,282 | -2.8% | 0.01% | -18.2% |
| Q2 2020 | $3,329,000 | +107.2% | 45,536 | -3.6% | 0.01% | +57.1% |
| Q1 2020 | $1,607,000 | -39.7% | 47,244 | -3.6% | 0.01% | -22.2% |
| Q4 2019 | $2,667,000 | +27.5% | 49,002 | -2.2% | 0.01% | +12.5% |
| Q3 2019 | $2,091,000 | – | 50,107 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
| Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
| ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
| Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
| Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
| Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |